Nasdaq auph.
At Aurinia, we embrace the possibility to change the trajectory of autoimmune diseases with unmet needs. With a growing pipeline and a dynamic team of proven experts, our work is patient-centric and driven by a sense of urgency. See how we are poised to deliver on our mission. Learn More.
Instrument Name Aurinia Pharm Ord Instrument Symbol (AUPH-Q). Instrument Exchange NASDAQ · Why Aurinia Pharmaceuticals Stock Is Slumping Today · Why Aurinia ...The new research reports from Fundamental Markets, available for free download at the links above, examine B Communications Ltd. (NASDAQ:BCOM), Student Transportation Inc (NASDAQ:STB), Aurinia ...Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shares Lagging The Industry But So Is The Business (Simply Wall St.) +5.35%. Jun-01-23 09:00AM LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids AloneAurinia’s (NASDAQ:AUPH) price movement over the last 12 months seems predicated on 3 things - key management changes, lackluster lupkynis sales, and most importantly, discontinuous whispers of M ...View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Dec 4, 2023 · Avid Bioservices Inc (NASDAQ:CDMO)’s Major holders. Insiders own 0.82% of the company shares, while shares held by institutions stand at 108.12% with a share float percentage of 109.02%. Investors are also buoyed by the number of investors in a company, with Avid Bioservices Inc having a total of 253 institutions that hold shares in the company. NASDAQ: AUPH Aurinia Pharmaceuticals. Market Cap. $1B. Today's Change (1.44%) $0.13. ... (AUPH 1.44%), a company focused on developing treatments for autoimmune diseases, saw its share price fall ...
This page of Aurinia Pharmaceuticals (AUPH) displays a brief signal update and a market outlook, as well as a candlestick chart showing the last detected ...NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...
Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAurinia Pharmaceuticals Inc. NASDAQ: AUPH gapped up in heavy volume on the first trading day of the year and hasn’t looked back since. The Canadian biotech company launched LUPKYNIS two years ago as the first FDA-approved oral treatment for adults with active lupus nephritis (LN). This autoimmune disease affects more than …Avid Bioservices Inc (NASDAQ:CDMO) has a beta value of 1.52 and has seen 0.52 million shares traded in the recent trading session. The company, currently valued at $305.42M, closed the recent trade at $4.84 per share which meant it lost -$0.15 on the day or -3.11% during that session. ... (NASDAQ:AUPH) has a beta value of 1.39 and has …December 4, 2023. Company. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a beta value of 1.39 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $1.27B, closed the recent trade at $8.82 per share which meant it lost -$0.24 on the day or -2.60% during that session.
Sep 27, 2023 · It has been quite some time since we last took a look at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). This small biopharma has been somewhat of a roller coaster ride for its shareholders in recent ...
Dec 4, 2023 · Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders Insiders own 2.02% of the company shares, while shares held by institutions stand at 60.74% with a share float percentage of 61.99%. Investors are also buoyed by the number of investors in a company, with Aldeyra Therapeutics Inc having a total of 142 institutions that hold shares in the ...
Nov 20, 2023 · Nov. 20, 2023, 12:38 PM. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the ... Jul 3, 2023 · Aurinia Pharmaceuticals AUPH rose almost 5.8% on Jun 30, as management announced that it is exploring strategic alternatives for the company’s future. AUPH will consider a range of options ... Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH) jumped ~11% pre-market Wednesday after announcing that the company is on track to receive two new patents in the U.S. and EU covering its ...July 15, 2020 at 10:15 AM · 4 min read. Steven Cohen ( Trades, Portfolio ), head of Point72 Asset Management, disclosed this week his firm upped its stake in Otonomy Inc. (NASDAQ:OTIC) by 1,354. ...See the latest Aurinia Pharmaceuticals Inc stock price (AUPH:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Find the latest Financials data for Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a ...
Cramer said Aurinia Pharmaceuticals Inc. AUPH is a Canadian company that "I don’t really have a lot of confidence in, and I’m not recommending any companies that are losing money hand over ...Jul 18, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ... Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is a speculative stock and it's not making any money, said Cramer. He prefers Nokia (NYSE:NOK) over Ericsson (NASDAQ:ERIC).Shares of the autoimmune disease specialist Aurinia Pharmaceuticals ( AUPH -1.04%) are poised for a tough session today. Ahead of the opening bell, the drugmaker's share price cratered by more ...Aurinia Pharmaceuticals (AUPH) closed the last trading session at $9.80, gaining 0.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...
The company has $337.90 million in cash and $93.21 million in debt, giving a net cash position of $244.69 million or $1.70 per share. Cash & Cash Equivalents.
Aurinia Pharmaceuticals (NASDAQ:AUPH) has been subject to buyout speculations for well over a year now. It was as early as May 2021, when The Times mentioned AstraZeneca ( AZN ) or GSK ( GSK ) are ...NASDAQ: AUPH Aurinia Pharmaceuticals. Market Cap. $1B. Today's Change (1.44%) $0.13. ... (AUPH 1.44%), a company focused on developing treatments for autoimmune diseases, saw its share price fall ...As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.The public float for AUPH is 130.54M, and at present, short sellers hold a 13.23% of that float. The average trading volume of AUPH on November 20, 2023 was 1.70M shares. AUPH) stock’s latest price update. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)’s stock price has increased by 3.08 compared to its previous closing price of 8.60.AUPH Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $14.20 with a high forecast of $15.00 and a low forecast of $13.00. The average price target represents a 71.29% change from the last price of $8.29.Aurinia Pharmaceuticals' (AUPH) Buy Rating Reaffirmed at Oppenheimer. FRIDAY, MAY 7, 2021. Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP)'s stock had its "buy" rating reaffirmed by stock analysts ...
Fintel reports that on July 6, 2023, Cantor Fitzgerald reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight recommendation. Analyst Price Forecast Suggests 64.02% Upside
Meanwhile, Jefferies analyst Maury Raycroft, with a Buy rating on Aurinia ( AUPH ), has cut the per share target to $29 from $34 to imply a premium of ~142% to the last close. Raycroft attributes ...
Dec 4, 2023 · December 4, 2023. Company. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a beta value of 1.39 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $1.27B, closed the recent trade at $8.82 per share which meant it lost -$0.24 on the day or -2.60% during that session. What happenedAurinia Pharmaceuticals (NASDAQ: AUPH), a company focused on developing treatments for autoimmune diseases, saw its share price fall by more than 5% in early trading on Monday. The ...On the other hand Veracyte Inc (NASDAQ:VCYT) is the least popular one with only 12 bullish hedge fund positions. Fitbit Inc (NYSE:FIT) is not the most popular stock in this group but hedge fund ...Aurinia Pharmaceuticals AUPH stock was up about 11% on Tuesday after the company announced that the United States Patent and Trademark Office (USPTO) issued a new and refined method-of-use patent ...AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...Real time Aurinia Pharmaceuticals (AUPH) stock price quote, stock graph, news & analysis. Aurinia Pharmaceuticals Inc stock price live 8.64, this page displays NASDAQ AUPH stock exchange data. View the AUPH premarket stock price ahead of the market session or assess the after hours quote.AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...Shares of Aurinia Pharmaceuticals Inc. AUPH gained 13.2% on Dec 2, following fresh rumors of a potential buyout. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on ...Nov 15, 2023 · Below is a chart showing AUPH's trailing twelve month trading history, with the $9 strike highlighted in orange: Phillips 66 (Symbol: PSX) options are showing a volume of 21,547 contracts thus far ...
Dec 1, 2023 · View Aurinia Pharmaceuticals Inc AUPH investment & stock information. Get the latest Aurinia Pharmaceuticals Inc AUPH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Get the latest CymaBay Therapeutics Inc (CBAY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...Instagram:https://instagram. prvaxwhy are energy stocks downsilver dollar 1921 coin valueshpk stock forecast Nov 29, 2023 · The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00. Learn more on AUPH's analyst rating history. Do Wall Street analysts like Aurinia Pharmaceuticals more than its competitors? financial planning omahaotcmkts prtyq The OCUL stock price is -140.48% off its 52-week high price of $7.96 and 39.58% above the 52-week low of $2.00. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.72 million shares traded. The 3-month trading volume is 808.59K shares. The consensus among analysts is that Ocular Therapeutix Inc (OCUL ... electric stocks to buy Avid Bioservices Inc (NASDAQ:CDMO) has a beta value of 1.52 and has seen 0.52 million shares traded in the recent trading session. The company, currently valued at $305.42M, closed the recent trade at $4.84 per share which meant it lost -$0.15 on the day or -3.11% during that session. ... (NASDAQ:AUPH) has a beta value of 1.39 and has …Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ...